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A B S T R A C T
Sudden severe headache is a cardinal symptom and the most common complaint amongst patients presenting
with aneurysmal subarachnoid hemorrhage. The multifactorial etiology of these headaches makes pharma-
cotherapy problematic. Current aneurysmal subarachnoid hemorrhage guidelines have limited or no re-
commendations for headache treatment. Our institution utilizes a multimodal pharmacotherapy protocol in the
management of aneurysmal subarachnoid hemorrhage headache. The purpose of this study was to evaluate the
efficacy of the current aneurysmal subarachnoid hemorrhage headache treatment approach at our institution.
This was a retrospective cohort study of patients presenting with aneurysmal subarachnoid hemorrhage. A
multimodal aneurysmal subarachnoid hemorrhage headache treatment protocol was implemented in February
2014. After an eight-month washout period, patients treated between September 2014 and November 2017
represented the study cohort. Data collected included severity of aneurysmal subarachnoid hemorrhage and
headache, interventions to secure the aneurysm, pain score response related to specific analgesic administered,
and discharge status. Multivariate analysis and linear regression were used to identify predictors of treatment
efficacy. A total of 249 patients were identified in the study cohort. The majority of patients were female (61.4%)
with a median age of 54 years (± 12.5), median Hunt and Hess score of 2 (interquartile range 2–3), and mean
length of hospitalization of 15.2 days. Magnesium infusion had the largest reduction in mean pain score com-
pared to baseline pain score (−0.75; p = 0.0002). In this retrospective cohort study involving patients pre-
senting with headache secondary to aneurysmal subarachnoid hemorrhage, no agent resulted in a clinically
significant improvement on headache pain scores.
1. Introduction
Sudden severe headache is a common complication of aneurysmal
subarachnoid hemorrhage (aSAH) [1,2]. The cause of headaches re-
lated to aSAH is likely multifactorial, with local inflammation of cere-
bral arteries, chemical irritation of the meninges by the blood in the
subarachnoid space, and intracranial pressure changes [3,4]. Over time,
red blood cells (RBCs) are degraded to oxyhemoglobin, inhibiting nitric
oxide and stimulating endothelin-1. In addition, release of reactive
oxygen species and free iron, as well as production of vasoactive
compounds, leads to oxidative damage and cerebral artery constriction.
This damage induces secondary inflammatory states and neuronal ex-
citatory activity through calcium influx and N-methyl-D-aspartate
(NMDA) receptors, thus contributing to cerebral vasospasm and likely
exacerbating severe headache [5]. Recent evidence also suggests there
may be a neuropathic component to these headaches as well [6].
Overall, the complicated multifactorial etiology of these headaches
makes targeted pharmacotherapy problematic. Current aSAH guide-
lines have limited or no recommendations for headache treatment
[7,8]. Use of common agents for headaches such as non-steroidal anti-
inflammatory agents (NSAIDs) and opioid analgesics are limited in
patients with aSAH by their respective risks. NSAIDs have the potential
to increase the risk of bleeding after aSAH, while opioid sedative effects
have the potential to obscure the neurologic exam in patients who re-
quire close monitoring for the detection of cerebral vasospasm. In ad-
dition, agents typically used for migraine (such as acetaminophen/bu-
talbital/caffeine or triptans) may cause cerebral vasoconstriction,
which may be deleterious in patients at risk of cerebral vasospasm [9].
Reports of success with magnesium and gabapentin have been pub-
lished, but are not definitive given the study design and small sample
size [5,7,9].
Due to the complicated multifactorial etiology and difficulty
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controlling headache pain our institution established a multimodal
protocol for the management of aSAH headache incorporating various
pharmacologic agents with different mechanisms of action in sequence.
The purpose of this study was to evaluate the efficacy of current aSAH
headache treatment at our institution. The hypothesis of this study was
that none of the agents in the current protocol have a significant impact
on headache scores.
2. Materials and methods
This study was a retrospective cohort study of adult patients pre-
senting to University of Kentucky HealthCare (UKHC) who were ad-
mitted with aSAH. The University of Kentucky Center for Clinical and
Translational Science Enterprise Data Trust was used to identify pa-
tients with the diagnosis codes for aSAH between September 2014 and
November 2017. The multimodal aSAH headache treatment protocol
(Fig. 1), was implemented in February 2014. After an eight-month
washout period, patients treated between September 2014 and No-
vember 2017 represented the study cohort. This cohort included pa-
tients ≥18 years of age, who received an analgesic for the treatment of
aSAH-associated headache, and had a hospital length of stay ≥3 days.
Patients were excluded if the subarachnoid hemorrhage was inflicted by
trauma, inadequate medication administration records or incomplete
medical records were present, or if they presented with Hunt and Hess
Grade V aSAH. Local institutional review board approval was obtained
via expedited review.
The study site is a Joint Commission accredited comprehensive
stroke center and a regional referral center for the management of
various types of stroke, particularly aSAH. Treatment of patients with
aSAH is largely reflective of guideline recommendations [7]. Aneurysm
embolization or clipping is typically performed within the first 24–48 h
after presentation when possible. Patients are routinely observed in the
intensive care unit for the first 7–14 days, depending on aSAH severity
and other clinical factors. Patients are prescribed nimodipine 60 mg
orally every 4 h. Euvolemia and normonatremia are targeted. Headache
management is typically followed by protocol (Fig. 1) for patients who
are oriented and able to interact with the nurse. Visual and physiologic
cues of pain are used in patients who are less responsive where the pain
score cannot be specifically enumerated. A computerized order set was
entered for each patient with the algorithm approach from Fig. 1. We
did not evaluate adherence to the algorithm in this study.
The primary outcome of this study was to evaluate the efficacy of
various medications used for headache, measured as the change in
patient reported pain scores two hours after medication administration.
Each patient’s pain scores (on a 0–10 point analog scale) were routinely
monitored by nursing staff to assess the efficacy of protocol-guided
analgesics before and after medication administration.
Data points collected included patient demographics such as age
and smoking history, pain scores through seven days, total number of
analgesic doses per day through seven days, aSAH characteristics (se-
verity and method of aneurysm intervention), and length of stay. Other
data included daily maximum and average patient scores through ad-
mission, total number of analgesic doses per day through admission,
pain score response related to specific analgesic administered, and need
for rescue therapy (administration of an opioid excluding codeine).
Multivariate analysis and linear regression were used to identify
treatment efficacy for each analgesic. Alpha was set at p < 0.05. All
statistical analysis was performed using SAS 9.4 (SAS Institute Inc.,
Cary, NC, USA).
3. Results
A total of 301 patients were identified within the designated time
period. Of those patients, 52 patients were excluded due to presentation
with Hunt and Hess Grade V aSAH. The demographics for the study
cohort are outlined in Table 1. The majority of patients were female
(61.4%) with a mean age of 54 years (± 12.5), and a median Hunt and
Hess score of 2 (interquartile range 2–3). The mean length of
Fig. 1. Acetaminophen is used first for headache pain. For patients with secured aneurysms, nurses may use NSAIDs or codeine products as second tier therapy if
headache pain persists. For patients with unsecured aneurysms (or those that have no angiographic evidence of aneurysms), only codeine products are available as
second tier therapy. If second tier therapy fails to improve headache pain, the nurse supplements magnesium intravenously to a serum concentration of> 2gm/dL. If
magnesium supplementation does not improve headache pain, a short course of dexamethasone is initiated.
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hospitalization was 15.2 days ± 11.8 and more than half of the pa-
tients reported previous or current tobacco use (50.8%). The daily
maximum pain score was typically between 5 and 7 (on a scale of 0–10)
for the study period (Fig. 2).
The details of the rate of use of each analgesic is described in
Table 2. Nearly all patients in the study cohort received acetaminophen
(98.8%) and magnesium (95.6%). Codeine (59.8%), ketorolac (28.1%),
and ibuprofen (27.7%) were also frequently used. NSAIDs (ketorolac
and ibuprofen) were used only in patients who underwent aneurysm
embolization or clipping, in order to reduce the risk of re-bleeding.
Oxycodone (15.3%) was used infrequently and typically as a last-line
option. Other intravenous opioid agents were used sparingly. Analge-
sics that were co-administered were not assessed. Gabapentin (11.6%)
was typically used as continuation of home therapy and rarely as a last-
line option.
When comparing pain score reduction before and after specific an-
algesic administration in the study cohort, several analgesics exhibited
a significant pain score reduction within 2 h of administration (Table 2,
Fig. 3). Magnesium had the largest reduction in mean pain score
(−0.75; p = 0.0002) followed by acetaminophen/butalbital/caffeine
(−0.6354; p = 0.0003), ketorolac (−0.60; =0.0002), and acet-
aminophen plus codeine (−0.57; p = <0.001). Oxycodone was the
only medication shown to increase the pain score 2 h after adminis-
tration, however, this was not statistically significant (0.428;
p = 0.089). Other common protocol options such as acetaminophen,
ibuprofen, dexamethasone, gabapentin, and hydrocodone did not de-
monstrate a significant pain reduction from the baseline pain score.
4. Discussion
In this retrospective cohort study involving patients with headache
secondary to aSAH, magnesium had the largest reduction in mean pain
score followed by acetaminophen/butalbital/caffeine, ketorolac, and
acetaminophen plus codeine. However, none of the agents were asso-
ciated with a clinically significant change in pain scores. Despite using a
multi-modal approach to pain management, patients with aSAH appear
to have treatment refractory headache which does not respond well to
pharmacotherapy, which corroborates with our first report of treatment
of headache in his population, as well as the experiences of other si-
milar centers [9,10].
While numerous options are available for analgesia in patients with
aSAH-associated headache, nearly all have aspects that limit their use
in this patient population. Acetaminophen was commonly used in the
current cohort with little efficacy. Hepatic injury with doses greater
than 3-4gm/day limits the dosing of acetaminophen in patients who do
not have an adequate therapeutic response. Acetaminophen/butalbital/
caffeine is commonly associated with rebound headache upon dis-
continuation. In addition, a previous univariate analysis suggested that
acetaminophen/butalbital/caffeine may be associated with early va-
sospasm in patients with aSAH, although this was not corroborated by
the multivariate analysis correcting for aSAH severity and age [9]. Al-
though acetaminophen/butalbital/caffeine lowered the mean pain
score in the current study cohort, the potential risk of early vasospasm
and exposure to the long-acting sedative (butalbital) should be con-
sidered and alternative pharmacotherapy may be more beneficial.
Opioids cause sedation in many patients, which could confound a pa-
tient’s neurologic exam during the vasospasm risk period, where de-
tection of subtle neurologic changes is of paramount importance.
In patients who undergo aneurysm embolization or clipping,
NSAIDs may be useful for headache. Ketorolac was used successfully in
the current study cohort, though not with high frequency relative to
other protocol options. However, ketorolac is not recommended to be
continued for more than 5 days due to hepatic and gastrointestinal
adverse effects, which limits the use of this agent to acute, short-term
therapy. Ibuprofen may also be used (not concomitantly with ketor-
olac), but had a less robust response in our cohort.
Opioids are typically reserved for refractory headache due to the
potential for sedation and dependence. Codeine plus acetaminophen
was used frequently in our patients with some success. It is not routine
practice to evaluate pharmacogenetic variability in these patients re-
garding codeine metabolism, so it is unknown if we used this agent in
patients who were hypometabolizers (and would likely have less ther-
apeutic response). Oxycodone was used less frequently and was asso-
ciated with a worsening of headache in the current cohort. This is likely
due to use in patients who have already failed numerous therapies and
who are likely to have little to no response to additional therapies as
Table 1
Patient demographics.
Study Cohort (n = 249)
Age (years) Mean (S.D.) 54.0 (12.5)
Gender (n, % female) 153 (61.4)
Weight (kg) Mean (S.D.) 85.1 (24.8)
History of tobacco use (n, %) 122 (50.8)
Hospital length of stay (days) Mean (S.D.) 15.2 (11.8)
Presenting Hunt & Hess Score Median (IQR) 2 (2–3)
Method of aneurysm intervention
Coiling (n, %) 161 (64.6)
Clipping (n, %) 9 (3.6)
Angio-negative/non-aneurysmal (n, %) 79 (31.7)
Fig. 2. The daily maximum pain score was typically between 5 and 7 (on a scale of 0–10) for the study period.
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well.
Several ancillary agents were used in the current cohort with
minimal response. Dexamethasone is the primary last-line option in the
protocol, thus it was used primarily in refractory cases of headache,
which may explain why it was not associated with a significant re-
duction in pain. Dexamethasone doses were given to patients in the
current study for reasons other than headache (eg. stridor), which may
have also tempered the effect on change in pain scores. More recently,
gabapentinoids have also been promoted as a potential option in aSAH
patients, as well as other types of headache [6]. The current cohort
infrequently received gabapentin and typically did so as continuation of
home therapy (which is our standard practice to continue agents such
as this which may have a withdrawal syndrome), so we are unable to
make definitive statements on this therapy. Patients that received ga-
bapentin did not have a statistical difference in mean pain reduction
after two hours. The issue of tapering gabapentin and how to handle
transitions of care issues for aSAH patients, who often suffer from
headache months after ictus, is not well-defined [2,6].
Given the single-center retrospective nature of this study, inherent
limitations such as the possibility for patient selection bias and co-
founding factors may exist. Changes in care over the time period may
have impacted outcomes. The subjective nature of pain and the use of
patient-reported pain scales, such as 10-point analog scale used in this
study, makes inter-patient pain score comparison challenging.
Documentation of acceptable pain levels for each patient was
inconsistent and not recorded as a result. To reduce this limitation, this
study focused on the change of pain scores, thus reducing inter-patient
variability. Patients who experience more pain may be evaluated more
frequently by nursing staff, therefore falsely elevating average pain
scores. To neutralize this potential for bias, we not only evaluated the
change in pain scores after each analgesic, but also considered the
maximum pain score for each day. The location and description of pain
was not differentiated and other causes of pain other than headache
may contribute to the patient’s overall pain. However, severe headache
is often the most common complaint and is the overriding source of
pain in this patient population. Additionally, despite the use of an
adequate wash-out time period, we are unable to determine if the aSAH
headache treatment algorithm was followed appropriately. It is well-
known that headache associated with aSAH can persist for many weeks,
so long-term treatment of headache in this population may not be re-
flected in the present study. Due to lack of documentation, the influence
of other factors which may affect headache such as past medical history
of headache or migraine, potential for withdrawal of social or recrea-
tional drugs, and the impact of anxiety or fear on headache were not
able to be analyzed. We were unable to evaluate the impact of an-
eurysm embolization or clipping on headache [11,12]. Finally, the in-
teraction of the various medications used in combination in the current
multi-modal approach may have impacted efficacy. The current ana-
lysis was unable to discern if certain combinations or a certain order of
therapy would be additive or synergistic for efficacy. Future prospective
Table 2
Pain score change before and after medication administration.
Medication Number of patients (%) Number of Doses Mean Pain score reduction (S.D.) P-value
Acetaminophen 246 (98.8%) 519 −0.185 (2.76) 0.1275
Acetaminophen/Codeine 149 (59.8%) 1122 −0.5731 (2.82) <0.0001
Acetaminophen/Fioricet 81 (32.5%) 288 −0.6354 (2.98) 0.0003
Acetaminophen/Hydrocodone 12 (4.8%) 52 −0.3077 (3.00) 0.4630
Ibuprofen 69 (27.7%) 56 −0.4643 (1.91) 0.0738
Ketorolac 70 (28.1%) 241 −0.6058 (2.47) 0.0002
Magnesium 238 (95.6%) 185 −0.7568 (2.68) 0.0002
Morphine 59 (23.7%) 35 −0.4000 (3.13) 0.4544
Oxycodone 38 (15.3%) 29 0.4828 (1.48) 0.089
Dexamethasone 152 (61%) 308 −0.0390 (2.5863) 0.7917
Gabapentin 29 (11.6%) 100 −0.3500 (2.4552) 0.1571
Fig. 3. The mean pain score change within 2 h following medication administration. Magnesium had the largest reduction in mean pain score (−0.75; p = 0.0002).
Oxycodone was the only medication to increase the pain score 2 h after administration, however, not shown to be statistically significant (0.428; p = 0.089).
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studies are necessary to identify what specific pharmacotherapy agents
are most effective to allow for modifications in aSAH headache treat-
ment protocols and the management of these complex patients.
5. Conclusion
In this retrospective cohort study involving patients presenting with
headache secondary to aSAH, several agents resulted in a statistically,
but not clinically, significant improvement in headache pain scores.
Pain scores for patients in the first week after aSAH are elevated and did
not change substantially through the week, independent of pharma-
cotherapy. Clinical and translational research is needed to identify safe
pharmacotherapy options that better target the headache associated
with aSAH.
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